leadf
logo-loader
viewScancell Holdings PLC

Scancell Holdings consortium gets government backing for Covid trial

The funding for a team, led by chief scientific officer, Prof Lindy Durrant, is coming from Innovate UK

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) said a consortium led by its chief scientific officer will receive government funding to kick start clinical development of a long-acting COVID-19 vaccine based on the company’s technology.

The drug developer said it expects to receive around £2mln of the sum awarded by Innovate UK, which should underwrite the majority of the costs of the phase I trial, which gets underway next year.

Heading the COVIDITY study will be Prof Lindy Durrant. She has teamed up with Prof Jonathan Ball and Dr James Dixon of Nottingham University and Prof Graham Pockley at Nottingham Trent.

Using technology that has been successfully applied with Scancell's lead cancer vaccine, SCIB1, the team wants to create a simple, safe, cost-effective and scalable vaccine.

The inoculation is expected to induce both “durable” T cell responses and virus neutralising antibodies to provide long-lasting immunity against COVID-19.

The idea is to create a second-generation jab with more potent, long-lasting responses, particularly in the elderly.

"We are delighted that Innovate UK has chosen to support our novel COVID-19 vaccine,” said Scancell chief executive Dr Clive Holloway.

“This funding will allow us to accelerate progress towards our planned phase I clinical trial, COVIDITY.”

Quick facts: Scancell Holdings PLC

Price: 11.5 GBX

LSE:SCLP
Market: LSE
Market Cap: £93.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read